Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Transcript
You've looked at real-world outcomes in patients with newly diagnosed multiple myeloma. How do your findings compare with previous research?
In this study we were looking at the outcomes of RVd [lenalidomide plus bortezomib and dexamethasone] versus Vd [bortezomib and dexamethasone] in real-world patients that were treated. And what was interesting is that in the overall population, the progression-free survival was improved with the triplet RVd by 26 months, but what we also were able to do in this, because it’s a real-world study, is look at subgroups, such as patients over the age of 80, and they benefitted equally.
With all of these subgroups I’m about to mention, all had more than a 20-month benefit. So, patients that were over age 80, Charlson Comorbidity Index more than 2, and also ECOG performance status of 2 or higher. So, often these 3 groups of patients are not included in studies, so you really don’t know what are the data. How many 80-year-old plus are included in a clinical trial? Almost none. So, it’s good to see that this triplet therapy in real world also still contributed to improved clinical outcomes with triplet therapy.
I would say, though, I think it’s important to use dose attenuation with these regimens to make sure that patients are tolerating them well. But clearly dose-attenuated RVd can be very well tolerated and is associated with excellent outcomes.
What is the importance of looking at real-world outcomes?
I think in general, we’re learning more and more that clinical trials are really important to get drugs approved, but we really do need to balance that with real-world evidence, recognizing all the disparities between the 2. And I think this is not just unique to myeloma, but in all of oncology, the clinical trial selection criteria are sometimes so rigid we really need to broaden them. And particularly for myeloma, where our patients are older, they’re going to have other cancers, they’re going to have renal dysfunction. If we’re not allowing these patients, how do we generalize study data to who we’re actually treating in the clinic?
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More